COX-2 silencing enhances tamoxifen antitumor activity in breast cancer in vivo and in vitro

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1385-1393

  Du, Ye ^a   Shi, Aiping ^a   Han, Bing ^a   Li, Sijie ^a   Wu, Di ^a   Jia, Hongyao ^a   Zheng, Chao ^a   Ren, Liqun ^a   Fan, Zhimin ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Antitumor activity; Breast cancer; COX 2 silencing; Tamoxifen

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYCLOOXYGENASE 2; PTGS2 PROTEIN, HUMAN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SMALL INTERFERING RNA; TAMOXIFEN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BIOSYNTHESIS; BREAST NEOPLASMS; CARCINOGENESIS; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; DRUG SCREENING; FEMALE; GENETICS; HEK293 CELL LINE; HUMAN; LENTIVIRINAE; MCF 7 CELL LINE; METASTASIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CARCINOGENESIS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLOOXYGENASE 2; FEMALE; HEK293 CELLS; HUMANS; LENTIVIRUS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894443593     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2299     Document Type: Article

References (41)

1. Jordan VC and O'Malley BW: Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 25: 5815-5824, 2007.
2. Brauch H and Jordan VC: Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach? Eur J Cancer 45: 2274-2283, 2009.
3. Cuzick J, Sestak I, Pinder SE, et al: Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 12: 21-29, 2011.
4. Roberts CG, Millar EK, O'Toole SA, et al: Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene 30: 3186-3197, 2011.
5. Garvin S, Nilsson UW and Dabrosin C: Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Br J Cancer 93: 1005-1010, 2005. (Pubitemid 41548394)
6. Qu Z, Van Ginkel S, Roy AM, et al: Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors. Cancer Res 68: 6232-6240, 2008.
7. Majeti BK, Lee JH, Simmons BH and Shojaei F: VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma. BMC Cancer 13: 213, 2013.
8. Chen CT and Hung MC: Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy. Am J Transl Res 5: 393-403, 2013.
9. Breinig M, Schirmacher P and Kern MA: Cyclooxygenase-2 (COX-2) - a therapeutic target in liver cancer? Curr Pharm Des 13: 3305-3315, 2007. (Pubitemid 350201686)
10. Stasinopoulos I, O'Brien DR, Wildes F, Glunde K and Bhujwalla ZM: Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Mol Cancer Res 5: 435-442, 2007. (Pubitemid 46903952)
11. de Heer P, Sandel MH, Guertens G, et al: Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. Cancer Chemother Pharmacol 62: 811-819, 2008.
12. Narayanan BA, Narayanan NK, Davis L and Nargi D: RNA interference- mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol Cancer Ther 5: 1117-1125, 2006. (Pubitemid 43881303)
13. Singh-Ranger G, Salhab M and Mokbel K: The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat 109: 189-198, 2008.
14. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT and De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56: 549-580, 2004. (Pubitemid 39658463)
15. Hasegawa K, Ichikawa W, Fujita T, et al: Expression of cyclooxygenase-2 (COX-2) mRNA in human colorectal adenomas. Eur J Cancer 37: 1469-1474, 2001. (Pubitemid 32744675)
16. Kumar BN, Rajput S, Dey KK, et al: Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC Cancer 13: 273, 2013.
17. Lacroix I, Lapeyre-Mestre M, Bagheri H, et al: Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care. Fundam Clin Pharmacol 18: 201-206, 2004. (Pubitemid 38491294)
18. Rudnick DA, Shikapwashya O, Blomenkamp K and Teckman JH: Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency. Hepatology 44: 976-982, 2006. (Pubitemid 46489562)
19. Park JW, Park JE, Lee JA, Lee CW and Kim CM: Cyclooxygenase-2 (COX-2) is directly involved but not decisive in proliferation of human hepatocellular carcinoma cells. J Cancer Res Clin Oncol 132: 184-192, 2006.
20. Wang R, Wang X, Lin F, Gao P, Dong K and Zhang HZ: shRNA-targeted cyclooxygenase (COX)-2 inhibits proliferation, reduces invasion and enhances chemosensitivity in laryngeal carcinoma cells. Mol Cell Biochem 317: 179-188, 2008.
21. Lin T, Gu J, Zhang L, et al: Enhancing adenovirus-mediated gene transfer in vitro and in vivo by addition of protamine and hydrocortisone. J Gene Med 5: 868-875, 2003. (Pubitemid 40310411)
22. Coleman JE, Huentelman MJ, Kasparov S, et al: Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol Genomics 12: 221-228, 2003. (Pubitemid 37139701)
23. Deglon N, Tseng JL, Bensadoun JC, et al: Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum Gene Ther 11: 179-190, 2000. (Pubitemid 30044050)
24. Tai MH, Weng CH, Mon DP, Hu CY and Wu MH: Ultraviolet C irradiation induces different expression of cyclooxygenase 2 in NIH 3T3 cells and A431 cells: the roles of COX-2 are different in various cell lines. Int J Mol Sci 13: 4351-4366, 2012.
25. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR and Katzenellenbogen BS: Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144: 4562-4574, 2003. (Pubitemid 37204856)
26. Renoir JM, Bouclier C, Seguin A, Marsaud V and Sola B: Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells. J Mol Endocrinol 40: 101-112, 2008. (Pubitemid 351586820)
27. Zheng J and Yao Z: Effect of tamoxifen on apoptosis and drug resistance of breast cancer cells in vitro. Zhonghua Zhong Liu Za Zhi 22: 55-57, 2000 (In Chinese).
28. Thiantanawat A, Long BJ and Brodie AM: Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res 63: 8037-8050, 2003. (Pubitemid 37466743)
29. Rajput S, Kumar BN, Sarkar S, et al: Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancer. PLoS One 8: e61342, 2013.
30. Blackwell KL, Haroon ZA, Shan S, et al: Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res 6: 4359-4364, 2000.
31. Marson LP, Kurian KM, Miller WR and Dixon JM: The effect of tamoxifen on breast tumour vascularity. Breast Cancer Res Treat 66: 9-15, 2001. (Pubitemid 32397937)
32. Garvin S and Dabrosin C: Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res 63: 8742-8748, 2003. (Pubitemid 38064052)
33. McNamara DA, Harmey J, Wang JH, Kay E, Walsh TN and Bouchier-Hayes DJ: Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo. Eur J Surg Oncol 27: 714-718, 2001. (Pubitemid 33085539)
34. Ruohola JK, Valve EM, Karkkainen MJ, Joukov V, Alitalo K and Harkonen PL: Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 149: 29-40, 1999. (Pubitemid 29236221)
35. Liu H, Xiao J, Yang Y, et al: COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer. Microvasc Res 82: 131-140, 2011.
36. Mallen SR, Essex MN and Zhang R: Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin 27: 1359-1366, 2011.
37. Rezende RM, Paiva-Lima P, Dos Reis WG, Camelo VM, Bakhle YS and de Francischi JN: Celecoxib induces tolerance in a model of peripheral inflammatory pain in rats. Neuropharmacology 59: 551-557, 2010.
38. Du G, Yonekubo J, Zeng Y, Osisami M and Frohman MA: Design of expression vectors for RNA interference based on miRNAs and RNA splicing. FEBS J 273: 5421-5427, 2006. (Pubitemid 44772398)
39. Stegmeier F, Hu G, Rickles RJ, Hannon GJ and Elledge SJ: A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA 102: 13212-13217, 2005. (Pubitemid 41325003)
40. Samakoglu S, Lisowski L, Budak-Alpdogan T, et al: A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat Biotechnol 24: 89-94, 2006. (Pubitemid 43083171)
41. Emdad L, Lebedeva IV, Su ZZ, et al: Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy. J Cell Physiol 210: 549-559, 2007. (Pubitemid 44956899)